As a young medical school graduate in the ’70s, Jacques Bernier ignored warnings that drugs were about to replace radiotherapy. He believed that new technology would make it safer and more effective. Today, he has [more]
Bringing the new wave of targeted cancer drugs to the market poses new challenges for researchers and clinicians. It is not enough to design a smart drug to hit a molecular target. Researchers need to [more]
Cancer drugs often deliver less than they promise. The BDA believes the problem may lie not in the drugs themselves, but in the way they are targeted, tested and used. It organises regular get-togethers where [more]